Dr. Dan LIU is currently the Managing Partner of Pivotal BioVenture Partners, in charge of Life Sciences Investment in China. He was the Senior Partner and Managing Partner / Investment Committee Member of several funds at CDH Investments, and was responsible for the investment in the Healthcare sector, including GemPharmatech (688046.SH), HitGen (688222.SH), I-Mab (IMAB.O), Maixin Biotech & Beijing Strong Biotechnologies (300406), BrainCo, and other successful deals.

Before joining CDH Investments, Dr. LIU worked at Bain & Company in the health and consumer sectors consulting businesses. He has served and led strategic projects for several large multinational pharmaceutical and device companies at that time. Dr. LIU has nearly 20 years of experience in the health industry in many fields, including research, business, management, consulting, and investment.

Dr. LIU is a well-known investor in China's healthcare and wellness industry. He also serves as a member and senior expert in several industry associations and a review expert of many provincial and municipal technology and talent programs. He was awarded as “TOP 50 Outstanding Investors in China”, “40 Investors Under 40 Years Old”, and “Top 10 Investors in Health Sector” by many credible Investment Communities and Entrepreneurship Zones.